Imagine a world where a single 3D printing file format can seamlessly bridge the gap between design and production, eliminating errors and ensuring consistency across diverse technologies and industries. This is no longer a distant dream but a reality with the 3D Manufacturing Format (3MF), a
In a striking reaction to President Donald Trump’s aggressive tariff threats designed to ramp up domestic production, pharmaceutical powerhouses are channeling billions into expanding manufacturing within the United States, signaling a major shift in response to political pressure. Industry leaders
In the ever-evolving landscape of pharmaceuticals, pharmacovigilance (PV) stands as a cornerstone of patient safety, tasked with the critical mission of monitoring and assessing adverse events (AEs) linked to drugs, while traditional approaches struggle under escalating workloads and regulatory
AstraZeneca, a major UK-based pharmaceutical company, has committed to a transformative $50 billion investment in its U.S. operations. This strategic initiative focuses on enhancing its manufacturing and research capabilities, aiming to secure a significant share of the American market by
In recent years, the U.S. pharmaceutical industry has been navigating the complex landscape of international trade policies and their implications on drug manufacturing and pricing. Central to this discussion are the tariffs proposed by the Trump administration, which have placed a spotlight on the
Amid significant legislative advancements, Johnson & Johnson (J&J) embarks on a pivotal journey to transform the pharmaceutical manufacturing landscape in the United States. By committing a staggering $55 billion towards domestic production initiatives, J&J aims to shed reliance on international
